KVUE

#2793
Kenvue Inc. Common Stock
0.1 7 USD
-99.02%
Secteur: Consommateur Défensif
Base: USD
Devise de Profit: USD
Range quotidien
0.17
0.18
Range Annuel
0.17
19.18
Changement quotidien
-99.02%
Changement Mensuel
-99.00%
Evolution sur 6 mois
-99.00%
Changement Annuel
-98.85%
Clôture Précédente
17.6 8
Open
0.1 8
Low
0.1 7
High
0.1 8
Volume
3 185
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques Dividendes
Trimestriel Annuel
Compte de résultat Bilan Flux de trésorerie
Valeur Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25 TTM

Kenvue Inc. Common Stock

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey. Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index. CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.

Nouvelles